Press Release   

Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Files New Drug Application for Ampligen as Treatment
for Chronic Fatigue Syndrome

Thursday October 11, 10:00 am ET

NDA of Investigational Drug Includes Four Well-Controlled Trials, More Than
1,200 Trial Subjects and 90,000 Doses


PHILADELPHIA, Oct. 11, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc.
(AMEX:HEB - News) announced today that it has filed a New Drug Application
(NDA) with the U.S. Food and Drug Administration (FDA) for its experimental
therapeutic, Ampligen(r), also known as Poly I : Poly C12U, to treat Chronic
Fatigue Syndrome (``CFS'').